Vol.64 No.4 July 2016

Susceptibilities of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2012

Keizo Yamaguchi¹⁾, Yoshikazu Ishii²⁾, Kazuhiro Tateda²⁾, Chikara Shimizu³⁾, Akira Suwabe⁴⁾, Mitsuo Kaku⁵⁾, Akira Hishinuma⁶⁾, Shigefumi Maesaki⁷⁾, Mitsuru Murata⁸⁾, Tetsuya Matsumoto⁹⁾, Hinako Murakami¹⁰⁾, Yoshihito Otsuka¹¹⁾, Masato Maekawa¹²⁾, Tetsuya Yagi¹³⁾, Yuka Yamagishi¹⁴⁾, Shinichi Fujita¹⁵⁾, Yukio Hida¹⁶⁾, Kaname Nakatani¹⁷⁾, Satoshi Ichiyama¹⁸⁾, Ikuko Fujimoto¹⁹⁾, Hisashi Kohno²⁰⁾, Kazuyuki Okuda²¹⁾, Nobuchika Kusano²²⁾, Yukinori Kurokawa²³⁾, Yaeko Watanabe²⁴⁾, Kiyoshi Negayama²⁵⁾, Hitoshi Miyamoto²⁶⁾, Makiko Kiyosuke²⁷⁾, Kouichi Mashiba²⁸⁾, Katsunori Yanagihara²⁹⁾, Yosuke Aoki³⁰⁾ and Kazufumi Hiramatsu³¹⁾

¹⁾Department of Advanced and Integrated Analysis of Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, Tokyo, Japan
²⁾Department of Microbiology and Infectious Diseases, Toho University School of Medicine
³⁾Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital
⁴⁾Central Clinical Laboratory, Iwate Medical University Hospital
⁵⁾The Department of Laboratory Medicine, Tohoku University Hospital
⁶⁾Department of Infection Control and Clinical Laboratory Medicine, Dokkyo Medical University
⁷⁾Department of Infectious Disease and Infection Control, Saitama Medical University
⁸⁾Department of Laboratory Medicine, Keio University Hospital
⁹⁾Department of Microbiology, Tokyo Medical University
¹⁰⁾Department of Clinical Laboratory, Toho University Omori Medical Center
¹¹⁾Laboratory of Medicine, Kameda Medical Center
¹²⁾Department of Laboratory Medicine, Hamamatsu University School of Medicine
¹³⁾Department of Infectious Diseases, Nagoya University Hospital
¹⁴⁾Department of Clinical Infectious Diseases, Aichi Medical University Hospital
¹⁵⁾Department of Infection Control and Prevention, Kanazawa University Hospital
¹⁶⁾Department of Clinical Laboratories, University of Fukui Hospital
¹⁷⁾Central Clinical Laboratories, Mie University Hospital
¹⁸⁾Department of Clinical Laboratory Medicine and Infectious Diseases, Kyoto University Graduate School of Medicine
¹⁹⁾Clinical Laboratory, Nara Medical University Hospital
²⁰⁾Department of Clinical Laboratory, Tenri Hospital
²¹⁾Clinical Sciences and Laboratory Medicine, Kansai Medical University Hirakata Hospital
²²⁾Department of Clinical Laboratory, Department of Infectious Diseases, Okayama University Hospital
²³⁾Central Clinical Laboratory, Kawasaki Medical School Hospital
²⁴⁾Department of Laboratory Medicine, Hiroshima Prefectural Hospital
²⁵⁾Department of Clinical Laboratory, Kagawa University Hospital
²⁶⁾Department of Clinical Laboratory, Ehime University Hospital
²⁷⁾Department of Clinical Chemistry and Laboratory Medicine, Kyushu University Hospital
²⁸⁾Department of General Medicine・Department of Clinical Laboratory, Kitakyushu Municipal Medical Center
²⁹⁾Laboratory Medicine, Nagasaki University Hospital
³⁰⁾Division of Infectious Disease and Hospital Epidemiology, Saga University Hospital
³¹⁾Clinical Laboratory Center, Oita University Hospital

Abstract

Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin (TAZ/PIPC) in 3,952 bacterial strains isolated in 2012 were conducted in Japan. β-lactamase production was investigated in over 80% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Providencia spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group. Extended spectrum β-lactamase-producing strains in E. coli, K. pneumoniae and P. mirabilis were 19.0%, 7.2% and 8.2%, respectively. Metallo-β-lactamase producers in P. aeruginosa and Acinetobacter spp. were 1.0% and 0.4%, respectively, and no strain of E. cloacae and S. marcescens was detected. Susceptibility of 3,952 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute or European Committee on Antimicrobial Susceptibility testing were distributed from 79.2% in E.cloacae to 100% in methicillin-susceptible S. aureus, coagulase-negative staphylococci, M. catarrhalis, P. mirabilis, indole-positive Proteus spp. and H. influenzae including β-lactamase-negative ampicillin-resistant strains. When compared with those in previous investigations conducted in 2010, the susceptibility to TAZ/PIPC had not changed. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for infectious diseases.

Key word

tazobactam/piperacillin, β-lactamase, susceptibility, CLSI, EUCAST

Received

August 13, 2015

Accepted

February 16, 2016

Jpn. J. Chemother. 64 (4): 668-680, 2016